2026-09-20T08:57:35Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/1556272024-07-11T03:25:13Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022

Shih, William M. Arnold, Olivia Jane Young Harvard-MIT Program in Health Sciences and Technology 2024-07-10T20:20:21Z 2024-07-10T20:20:21Z 2024-05 2024-06-11T21:12:46.593Z https://hdl.handle.net/1721.1/155627 0000-0002-2252-6623 DNA origami utilizes the complementary Watson and Crick base pairing of DNA to self-assemble highly programmable nanoparticles. These nanoparticles have distinct advantages over other nanoparticle delivery platforms, including polymeric and lipid nanoparticles, in that they offer precise nanoscale resolution control over the attachment of therapeutic cargo, while other nanoparticle platforms only offer control over average ligand density. In this thesis, we demonstrate the therapeutic utility of DNA origami for cancer and infectious diseases. First, we demonstrate that modulating the nanoscale arrangement of an adjuvant enhances the efficacy of cancer vaccines. Second, we demonstrate that this DNA origami nanoparticle can be used as a modular delivery vehicle for infectious disease associated antigens, enabling rapid response during pandemic situations. Third, we demonstrate the conjugation of CD40 ligand, an immune-activating molecule, onto the DNA origami nanoparticle, and describe initial investigations into the diverse spatial arrangements of CD40L and preliminary effects on the immune response. Collectively, these studies illustrate the potential of DNA origami as a therapeutic for various disease areas, as well as its potential as a tool for investigating biological receptor-ligand interactions. Ph.D. Massachusetts Institute of Technology In Copyright - Educational Use Permitted Copyright retained by author(s) https://rightsstatements.org/page/InC-EDU/1.0/ Therapeutic applications of DNA origami-based programmable nanoparticles Thesis application/pdf Doctoral Doctor of Philosophy Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="a88558bd-a69d-4f4a-9bc6-81671bf88066"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Title>Therapeutic applications of DNA origami-based programmable nanoparticles</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2024-05</PublicationDate> <Authors> <Author> <DisplayName>Arnold, Olivia Jane Young</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>https://rightsstatements.org/page/InC-EDU/1.0/</License> <Abstract>DNA origami utilizes the complementary Watson and Crick base pairing of DNA to self-assemble highly programmable nanoparticles. These nanoparticles have distinct advantages over other nanoparticle delivery platforms, including polymeric and lipid nanoparticles, in that they offer precise nanoscale resolution control over the attachment of therapeutic cargo, while other nanoparticle platforms only offer control over average ligand density. In this thesis, we demonstrate the therapeutic utility of DNA origami for cancer and infectious diseases. First, we demonstrate that modulating the nanoscale arrangement of an adjuvant enhances the efficacy of cancer vaccines. Second, we demonstrate that this DNA origami nanoparticle can be used as a modular delivery vehicle for infectious disease associated antigens, enabling rapid response during pandemic situations. Third, we demonstrate the conjugation of CD40 ligand, an immune-activating molecule, onto the DNA origami nanoparticle, and describe initial investigations into the diverse spatial arrangements of CD40L and preliminary effects on the immune response. Collectively, these studies illustrate the potential of DNA origami as a therapeutic for various disease areas, as well as its potential as a tool for investigating biological receptor-ligand interactions.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>